Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

photodynamic therapy with verteporfin and surgical treatments. Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

Phase 1b clinical data underpins sozinibercept's potential as a novel, first-in-class VEGF-C/D 'trap' to improve visual and anatomic outcomes in DME< ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Abnormalities of the vitreoretinal interface may contribute to important retinal pathologies such as diabetic retinopathy, diabetic macular edema and age-related macular degeneration. The ...

snu.ac.kr Background/Aims To provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Many people who have age-related macular degeneration don't know it. But ignoring this condition can lead to vision loss that can make it hard to perform everyday tasks. Many people who have ...

GA management involves identifying at-risk patients, assessing visual function, and referring for treatment when necessary.